The VISION trial is no longer recruiting. Tulane has two trials with a radionuclide attached to a PSMA ligand; the Th-227-PSMA antibody trial (currently recruiting) and the 67Cu-SAR-bisPSMA trial (beginning in September). Because he has bone metastases predominantly, I think the Th-227-PSMA-antibody trial might be preferable.
Hi as I said greatjohn on here has just undergone 1 course of LU-177 and I believe may be able to give you some advice - his blog identifies some of what he encountered - kindest Raoul
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.